



Organic & Biomolecular Chemistry

Accepted Manuscript



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

ARTICLE

Cite this: DOI: 10.1039/x0xx00000x

Exploiting the Narrow Gap of Rearrangement between the Substituents in the Vicinal Disubstitution Reactions of Diaryliodonium Salts with Pyridine N-sulfonamides

Received 00th January 2014,
Accepted 00th January 2014


DOI: 10.1039/x0xx00000x
www.rsc.org/

Yong Wang^{a, b} Ming Li,*^a Lirong Wen,^a Peng Jing,^b Xiang Su,^b Chao Chen*^b

The vicinal disubstitution reaction of diaryliodonium salts with pyridine N-sulfonamides were fully examined to afford o-pyridinium anilines. A pathway of N-arylation occurred at the amide group followed by a radical rearrangement was proposed for the reaction. The scope and more important, the electronic effect of substituents of this radical rearrangement were investigated.


Introduction

Polysubstituted benzene derivatives are highly important compounds in organic chemistry, natural product chemistry, pharmaceutical chemistry and materials science.¹ Consequently, there exists vast and long-termed demand for the regioselective synthesis of benzene derivatives with multiple substituents in organic synthesis. Besides assembly of benzene ring with acyclic small molecules (e.g. Reepke type reactions)², traditionally, more practical and efficient approaches towards polysubstituted benzene derivatives are based on aromatic substitution on C-H bond, which introduces a substituent on the given arene complying various substitution effect. A majority of these synthetic methodologies are based on electrophilic substitution³, but the additional substituent is normally introduced on meta-position (when R is EWG) or para-position (when R is EDG) (Scheme 1). Regio-selectively introducing substituent on the orth position of benzene ring is not so common and challenging. The utilization of directing group is mainly approach to introduce substituent on the orth C-H bond (via orth-metallation⁴ or C-H activation catalyzed by transition metal⁵), but the scope of this reaction is highly restricted by its nature. Additionally, Fries rearrangement is an efficient and regio-selective way to synthesize orth-substituted benzene derivatives.⁶



Scheme 1 Various types of introducing X groups on a given benzene ring via electrophilic substitution.

As part of our ongoing interest in the efficient synthesis of poly-substituted benzene derivatives, lately we reported a vicinal disubstitution reaction of diaryliodonium salts⁷ with pyridine N-oxides (eq 1).⁸ The reaction provided a selective manner to introduce two substituents at orth- and ipso-position of benzene ring simultaneously (eq 2). Interestingly, this vicinal disubstitution is also applicable to pyridine N-sulfonamide,⁹ where o-pyridinium aniline was isolated instead. In the primary communication, a pathway of N-arylation occurred at the amide group followed by a radical rearrangement was proposed for the reaction. In this account, we would like to report the scope and more important, the effect of substituents of this radical rearrangement.



Results and discussion

I Arylation of pyridinium sulfonamides with diaryliodonium salts

Firstly, the arylation products of pyridinium sulfonamides with diaryliodonium salts were prepared for the investigation of rearrangement. However, the arylation product **3aa** was unable to isolate by treatment of the reaction mixture of **1a** and **2a** with heating at 130 °C, while rearrangement reaction occurred to produce o-pyridinium aniline. Gladly, we found out when 10 mmol% of Cu(OTf)₂ was added, the arylation product **3aa** could be obtained in 57% yield at 75 °C (see detailed condition screening in SI). By this manner, a series of arylation products **3** of **2** with substituted iodonium salts **1** (scheme 2) were isolated in good to excellent yields (scheme 3). As shown in scheme 3, the iodonium salts bearing *o*-, *m*- or *p*-methyl and 2,4-dimethyl groups all worked well to give products **3a-3e**. Other iodonium salts with functional groups including fluoro, chloro, bromo and trifluoromethoxy groups on phenyl ring (**1f-1n**) were also tolerated in the Cu-catalyzed N-arylation reactions. When unsymmetric iodonium salts (**1g**, **1l** and **1m**) were used, the amination took place on the less hindered phenyl ring. Finally, several substituted pyridinium sulfonamides were chosen for the arylation reaction and the corresponding products were isolated also in good yield. Apparently, normal substituents on the pyridine ring didn't affect the arylation of sulfonamide group. All new compounds were characterized by ¹H, ¹³C NMR, ESI and HRMS. Furthermore, the structure of product **3kb** was confirmed by XRD analysis of its single crystal (figure 1).







Figure 1 Crystal structure of **3kb**. Counteranion of triflate and Hydrogen atoms were omitted for clarity.



Scheme 2 Diaryliodonium salts **1** and pyridinium sulfonamides **2** used in the reaction for the preparation of products **3**.






Scheme 3 Isolated yields of products 3.

II) Rearrangement of arylated pyridinium sulfonamides

Next, we investigated the formation of rearrangement products by reacting pyridinium salts with diaryliodonium salts. First, N-pyridine tosylamide **2a** was reacted with a range of diaryliodonium salts with various substituents on the aromatic ring **1a–1k** at 130 °C (eq 3, for the results see scheme 4). When the substituent R¹ or R² was electro-donating group such as H, methyl, dimethyl group, the reaction worked well to give rearrangement product. The structure of **4da** was further demonstrated by XRD analysis of its single crystal (figure 2).¹¹ In its crystal structure, it's clearly shown N-N bond was cleaved and inserted by a phenylene group. Moreover, the ipso-position of iodonium salt was substituted by tosylamide group and orth-position was substituted by pyridinium moiety. When the para-substituent R² was fluoroo- or chloro- atom, the reaction proceeded smoothly to give expected product. However, when the para-substituent R² was alternated to bromo-, trifluoromethoxy or trifluoromethyl group (**1n–1p**), the reaction couldn't afford rearrangement product. These results suggest electro-donating substituent on the phenyl ring of the diaryliodonium salts is prior for the rearrangement but electro-withdrawing one inhibits the rearrangement.

Scheme 4. Diaryliodonium trilates **1** (hexafluorophosphate for **1a**) and pyridinium sulfonamides **2a** used in the reaction for the preparation of products **4**.





Figure 2. Crystal structure of **4da**. Counteranion and Hydrogen atoms were omitted for clarity.



Scheme 5. Diaryliodonium trilates **1** and pyridinium N-sulfonamides with electron-donating groups **2** used in the reaction for the preparation of products **4**.


Encouraged by the above results, we attempted to investigate the influence of substitution of pyridinium sulfonamidate on the rearrangement. For this goal, a series of substituted pyridinium sulfonamidates were reacted with diaryliodonium salts to generate the rearrangement products (scheme 5). Interestingly, pyridinium sulfonamidates with electro-donating groups (**2b-e**) could react with electron-riched iodonium salts to give rearrangement products **4db-4de**. The reaction of **2c** with electron-deficient iodonium salts (**1h, 1k, 1n-1p**) didn't afford any rearrangement product.

| Pyridinium amide | Diaryliodonium salt | Product | Isolated yield (%) |
|------------------|---------------------|------------|--------------------|
| 2h | 1a | 4ah | 79 |
| | 1h | 4hh | 85 |
| 2f | 1a | 4af | 76 |
| | 1f | 4ff | 42 |
| 2c | 1h | 4hf | 75 |
| | 1k | 4kf | 75 |
| 2d | | 4nf | 68 |
| 2e | | 4of | 65 |
| 2c | 1o | | |


Scheme 6. Diaryliodonium trilates **1** (hexafluorophosphate for **1a**) and halogen-substituted pyridinium sulfonamidates **2** used in the reactions for the preparation of products **4**.

Halogen-substituted pyridinium sulfonamides showed more reactive to give rearrangement products (scheme 6). As proved, 3-chloropyridinium sulfonamides could react with diaryliodonium salts with bromo-, chloro- and trifluoromethoxy groups to generate the rearrangement products.


The reaction of diaryliodonium trilate **1q** and pyridinium sulfonamide **2a** could give the arylated product, which didn't undergo the rearrangement reaction. Overlong heating of the arylated product would afford decomposition product **7** presumably via radical reduction (eq 4).



The reaction of pyridinium sulfonamide with meta-substituted diaryliodonium trilate produced regio-isomer. For example, 3-chloro-pyridinium sulfonamide reacted with di(*m*-tolyl) iodonium trilate giving two isomers in a ratio of 3:2 (eq 5).



Finally, the effect of protecting group on the amide moiety was investigated. Similarly as tosylate group, pyridinium benzenesulfonamide amide **2g** worked with ditolyliodonium trilate **1d** also well to give rearrangement product in good yield (eq 6).



When protecting group on the amide moiety was changed to benzoate group, O-arylated product was obtained insteadly (eq 7). The structure of product **6a** was confirmed by XRD analysis of its single crystal (figure 3).¹²





Figure 3. Crystal structure of **6a**. Counteranion and Hydrogen atoms were omitted for clarity.

Conclusions

In this account, we have described a regio-selective way to synthesize benzene derivatives with vicinal disubstitution by the reaction of diaryliodonium salts with pyridinium N-sulfonamides. The reaction proceeds via the arylation of pyridinium N-sulfonamides and then key rearrangement of the arylated products **3** (Figure 4). Previous study and this work have proven that rearrangement is generally initiated by a homo-cleavage to give a radical pair: tosylate aniline radical A¹³ and pyridinium radical B¹⁴. The recombination of the radical pair would afford the final product **4** and this process was sensitively influenced by the substituents on the pyridinium ring and the phenyl ring, as shown in scheme 6. This result has shown us the nature of radical rearrangement resembling the electrophilic substitution on the phenyl ring (scheme 7).¹⁵





Figure 4. Plausible reaction mechanism.



Scheme 7. Influence of the substituents on the pyridinium ring and the phenyl ring on the rearrangement.

Experimental section

All the reactions were carried out in pre-dried a screwcapped tube with a Teflon-lined septum under N₂ atmosphere. Ph₂IPF₆ was purchased from Alfa-aeasar. Other diaryliodonium salts are Ar₂IOTf, because the activity of Ar₂IOTf is almost same to Ar₂IPF₆ (just a slight decrease) and Ar₂IOTf are easier to synthesized according to literature. All of the solvents were fresh distilled. Column chromatography was performed on silica gel (particle size 10–40 μm, Ocean Chemical Factory of Qingdao, China). ¹H NMR and ¹³C NMR spectra were recorded on a JEOL AL-300MHz or AL-400MHz spectrometer at ambient temperature with CDCl₃, CD₃OD and DMSO-D₆ as the solvent. Chemical shifts (δ) were given in ppm referenced to the residual proton resonance of CDCl₃ (7.26), CD₃OD (3.31) and DMSO-D₆ (2.50) to the carbon resonance of CDCl₃ (77.16), CD₃OD (49.00) and DMSO-D₆ (39.52). Coupling constants (J) were given in Hertz (Hz). The term m, dq, q, t, d, s referred to multiplet, doublet quartet, quartet, triplet, doublet, singlet. Mass spectra were obtained using Bruker Esquire ion trap mass spectrometer in positive mode.

Preparation of starting materials: Diaryliodonium salts were synthesized according to the literature procedures.⁷ N-pyridine tosylamides **2a–2f**, **2h**, N-pyridinium benzenesulfonated amide **2g** and N-pyridinium benzoated amides **5a–5b** were all synthesized according to the literature procedures.¹⁶

General procedure for the preparation of desired compound 3: Cu(OTf)₂ (0.05 mmol) was added to a mixture of appropriate N-tosylpyridinium imides or N-pyridine tosylamides (or N-pyridinium benzenesulfonated amide) **2** (0.5 mmol) and appropriate diaryliodonium salt **1** (0.5 mmol) in a sealed tube. Then the tube was evacuated and recharged with N₂ for 3 times. After 2 mL of dichloroethane was added, the tube was sealed and the mixture was allowed to stir at 75 °C for 12 h until completion of the reaction checked by TLC. At last the desired compound **3** was purified by silica gel column chromatography (dichloromethane/petroleum ether/methanol = 5:5:1) as a yellow solid.

General procedure for the preparation of desired compound 4: Cu(OTf)₂ (0.05 mmol) was added to a mixture of appropriate N-pyridine tosylamides (or N-pyridinium benzenesulfonated amide) **2** (0.5 mmol) and appropriate diaryliodonium salt **1** (0.5 mmol) in a sealed tube. Then the tube was evacuated and recharged with N₂ for 3 times. After 2 mL of dichloroethane was added, the tube was sealed and the mixture was allowed to stir at 130 °C for 48 h until completion of the reaction checked by TLC. At last the desired compound **4** was purified by silica gel column chromatography (dichloromethane/petroleum ether/methanol = 5:3:1) as a yellow solid.

1-(4-methyl-N-phenylphenylsulfonamido)pyridin-1-i-um hexafluorophosphate(V) (3aa).

yellow solid (134 mg, 0.28 mmol, 57%). ¹H NMR (301 MHz, METHANOL-D3): δ 9.47 (d, J = 5.8 Hz, 2H), 8.88 (t, J = 7.8 Hz, 1H), 8.31 (t, J = 7.2 Hz, 2H), 7.81 - 7.70 (m, 4H), 7.60 - 7.49 (m, 5H), 2.52 (s, 3H); ¹³C NMR (76 MHz, METHANOL-D3): δ 149.69, 148.07 (2×CH), 147.92, 137.53, 131.59, 131.41, 130.73 (2×CH), 130.40 (2×CH), 129.97 (2×CH), 129.03 (2×CH), 128.57 (2×CH), 20.54; ESI-MS: m/z calcd for C₁₈H₁₇N₂O₂S [M-PF₆]⁺: 325.1; found: 325.0; ESI-HRMS: m/z calcd for C₁₈H₁₇N₂O₂S [M-PF₆]⁺: 325.1005; found: 325.1005.

1-(4-methyl-N-(o-tolyl)phenylsulfonamido)pyridin-1-i-um trifluoromethanesulfonate (3ba).

yellow solid (188 mg, 0.39 mmol, 77%). ¹H NMR (400 MHz, METHANOL-D3) δ 9.40 (d, J = 5.9 Hz, 2H), 8.82 (t, J = 7.8 Hz, 1H), 8.25 (d, J = 7.4 Hz, 1H), 7.76 (d, J =

7.5 Hz, 1H), 7.69 (d, J = 8.3 Hz, 2H), 7.53 - 7.44 (m, 3H), 7.38 (t, J = 7.0 Hz, 2H), 2.50 (s, 3H), 2.41 (s, 3H); ¹³C NMR (101 MHz, METHANOL-D3) δ 149.40, 148.04, 147.73 (2×CH), 140.34, 135.78, 132.34, 132.01, 131.23, 130.73 (2×CH), 129.76 (2×CH), 129.24, 129.16 (2×CH), 127.70, 120.47 (q, J = 318.5 Hz), 20.51, 17.45; ESI-MS: m/z calcd for C₁₉H₁₉N₂O₂S [M-TFO]⁺: 339.1; found: 339.0; ESI-HRMS: m/z calcd for C₁₉H₁₉N₂O₂S [M-TFO]⁺: 339.1162; found: 339.1166.

1-(4-methyl-N-(m-tolyl)phenylsulfonamido)pyridin-1-i-um trifluoromethanesulfonate (3ca).

yellow solid (149 mg, 0.31 mmol, 61%). ¹H NMR (400 MHz, METHANOL-D3) δ 9.40 (d, J = 5.7 Hz, 2H), 8.83 (t, J = 7.8 Hz, 1H), 8.25 (dd, J = 7.6, 6.9 Hz, 2H), 7.72 (d, J = 8.4 Hz, 2H), 7.50 (dd, J = 13.3, 5.3 Hz, 4H), 7.41 - 7.33 (m, 2H), 2.49 (s, 3H), 2.36 (s, 3H); ¹³C NMR (101 MHz, METHANOL-D3) δ 149.59, 148.01 (2×CH), 147.82, 141.12, 137.44, 132.04, 131.64, 130.67 (2×CH), 130.02, 129.89 (2×CH), 129.01 (2×CH, 1×C), 125.46, 120.46 (q, J = 318.7 Hz), 20.48, 19.82; ESI-MS: m/z calcd for C₁₉H₁₉N₂O₂S [M-TFO]⁺: 339.1; found: 339.0; ESI-HRMS: m/z calcd for C₁₉H₁₉N₂O₂S [M-TFO]⁺: 339.1162; found: 339.1163.

1-(4-methyl-N-(p-tolyl)phenylsulfonamido)pyridin-1-i-um trifluoromethanesulfonate (3da).

yellow solid (220 mg, 0.45 mmol, 90%). ¹H NMR (301 MHz, METHANOL-D3): δ 9.46 (d, J = 6.5 Hz, 2H), 8.88 (t, J = 7.8 Hz, 1H), 8.30 (t, J = 6.8 Hz, 2H), 7.76 (d, J = 7.5 Hz, 2H), 7.61 (d, J = 8.1 Hz, 2H), 7.54 (d, J = 8.0 Hz, 2H), 7.36 (d, J = 8.1 Hz, 2H), 2.53 (s, 3H), 2.41 (s, 3H); ¹³C NMR (76 MHz, METHANOL-D3): δ 149.54, 147.93 (2×CH), 147.79, 142.48, 134.87, 131.65, 130.84 (2×CH), 130.66 (2×CH), 129.89 (2×CH), 129.02 (2×CH), 128.63 (2×CH), 120.50 (q, J = 316.5 Hz), 20.49, 19.92; ESI-MS: m/z calcd for C₁₉H₁₉N₂O₂S [M-TFO]⁺: 339.1; found: 339.0; ESI-HRMS: m/z calcd for C₁₉H₁₉N₂O₂S [M-TFO]⁺: 339.1162; found: 339.1161.

1-(N-(2,4-dimethylphenyl)-4-methylphenylsulfonamido)-pyridin-1-i-um trifluoromethanesulfonate (3ea).

yellow solid (138 mg, 0.28 mmol, 55%). ¹H NMR (301 MHz, METHANOL-D3): δ 9.03 (d, J = 5.8 Hz, 2H), 8.71 (t, J = 7.8 Hz, 1H), 8.19 (t, J = 6.9 Hz, 1H), 7.47 - 7.38 (m, 3H), 7.27 (dd, J = 14.5, 8.2 Hz, 4H), 2.42 (s, 6H), 1.74 (s, 3H); ¹³C NMR (76 MHz, METHANOL-D3): δ 146.75 (2×CH), 146.61, 144.46, 139.96, 139.46, 137.19, 134.52, 129.68 (2×CH), 128.64, 127.24 (2×CH), 126.76 (2×CH), 125.67, 125.24, 120.44 (q, J = 318.8 Hz), 20.19, 19.55, 16.31; ESI-MS: m/z calcd for C₂₀H₂₁N₂O₂S [M-TFO]⁺: 353.13; found: 353.2; ESI-HRMS: m/z calcd for C₂₀H₂₁N₂O₂S [M-TFO]⁺: 353.1318; found: 353.1317.

1-(N-(2-fluorophenyl)-4-methylphenylsulfonamido)pyridin-1-i-um trifluoromethanesulfonate (3fa).

yellow solid (199 mg, 0.41 mmol, 81%). ¹H NMR (301 MHz, DMSO-D6) δ 9.43 (d, J = 6.0 Hz, 2H), 8.87 (t, J = 7.7 Hz, 1H), 8.32 (t, J = 7.1 Hz, 2H), 8.00 (dd, J = 11.2, 4.3 Hz, 1H), 7.73 - 7.61 (m, 3H), 7.52 (d, J = 8.2 Hz, 2H), 7.49 - 7.35 (m, 2H), 2.46 (d, J = 9.8 Hz, 3H); ¹³C NMR (76 MHz, DMSO-D6) δ 159.56 (d, J' = 253.8 Hz), 150.81, 148.83 (2×CH), 147.81, 135.11 (d, J^3 = 8.6 Hz), 132.43, 131.93, 131.48 (2×CH), 130.91 (2×CH), 129.20 (2×CH), 126.50 (d, J^3 = 3.1 Hz), 124.36 (d, J^2 = 12.8 Hz) 121.23 (q, J = 322.1 Hz), 118.01 (d, J^2 = 19.7 Hz), 21.79; ESI-MS: m/z calcd for C₁₈H₁₆FN₂O₂S [M-TFO]⁺: 343.1; found: 343.0.; ESI-HRMS: m/z calcd for C₁₈H₁₆FN₂O₂S [M-TFO]⁺: 343.0911; found: 343.0912.

1-(N-(3-fluorophenyl)-4-methylphenylsulfonamido)pyridin-1-i-um trifluoromethanesulfonate (3ga).

yellow solid (185 mg, 0.38 mmol, 75%). ¹H NMR (400 MHz, METHANOL-D3) δ 9.40 (d, J = 5.9 Hz, 2H), 8.86 (t, J = 7.8 Hz, 1H), 8.28 (t, J = 7.2 Hz, 2H), 7.74 (d, J = 8.3 Hz, 2H), 7.58 - 7.48 (m, 5H), 7.36 - 7.27 (m, 1H), 2.49 (s, 3H); ¹³C NMR (101 MHz, METHANOL-D3) δ 162.91 (d, J' = 249.3 Hz), 149.91, 148.14 (3×CH), 138.42 (d, J^2 = 9.8 Hz), 131.79 (d, J^3 = 8.8 Hz), 131.25, 130.81 (2×CH), 130.03 (2×CH), 129.03 (2×CH), 124.26 (d, J^3 = 3.3 Hz), 120.48 (q, J = 318.8 Hz), 118.30 (d, J^2 =

21.1 Hz), 115.84 (d, J = 24.3 Hz), 20.50; ESI-MS: m/z calcd for $C_{18}H_{16}FN_2O_2S$ [M-TfO]⁺: 343.1; found: 343.0.; ESI-HRMS: m/z calcd for $C_{18}H_{16}FN_2O_2S$ [M-TfO]⁺: 343.0911; found: 343.0912.

1-(N-(4-fluorophenyl)-4-methylphenylsulfonamido)pyridin-1-i-um trifluoromethanesulfonate (3ha). yellow solid (209 mg, 0.43 mmol, 85%). ¹H NMR (400 MHz, DMSO-D6) δ 9.65 (d, J = 6.4 Hz, 2H), 8.89 (t, J = 7.3 Hz, 1H), 8.36 (t, J = 7.1 Hz, 2H), 7.93 - 7.84 (m, 2H), 7.72 (d, J = 8.1 Hz, 2H), 7.54 (d, J = 7.9 Hz, 2H), 7.41 (dd, J = 12.1, 5.1 Hz, 2H), 2.46 (s, 3H); ¹³C NMR (101 MHz, DMSO-D6) δ 163.86 (d, J' = 250.3 Hz), 150.57, 148.64 (2 \times CH), 147.64, 133.55, 132.71 (d, J^3 = 9.6 Hz), 131.82, 131.43 (2 \times CH), 130.78 (2 \times CH), 129.37 (2 \times CH), 121.21 (q, J = 322.4 Hz), 117.86 (d, J^2 = 23.2 Hz), 21.79; ESI-MS: m/z calcd for $C_{18}H_{16}FN_2O_2S$ [M-TfO]⁺: 343.1; found: 343.0.; ESI-HRMS: m/z calcd for $C_{18}H_{16}FN_2O_2S$ [M-TfO]⁺: 343.0911; found: 343.0912.

1-(N-(2-chlorophenyl)-4-methylphenylsulfonamido)pyridin-1-i-um trifluoromethanesulfonate (3ia). yellow solid (181 mg, 0.36 mmol, 71%). ¹H NMR (301 MHz, METHANOL-D3) δ 9.41 (d, J = 6.0 Hz, 2H), 8.84 (t, J = 7.7 Hz, 1H), 8.26 (t, J = 7.0 Hz, 1H), 8.06 (dd, J = 6.6, 1.8 Hz, 1H), 7.75 (d, J = 8.3 Hz, 2H), 7.61 - 7.48 (m, 5H), 2.49 (s, 3H); ¹³C NMR (76 MHz, METHANOL-D3) δ 149.89, 148.25, 148.16 (2 \times CH), 135.57, 133.79, 133.55, 131.64, 131.43, 131.20, 130.80 (2 \times CH), 129.82 (2 \times CH), 129.09 (2 \times CH), 128.90, 120.46 (q, J = 318.5 Hz), 20.55; ESI-MS: m/z calcd for $C_{18}H_{16}ClN_2O_2S$ [M-TfO]⁺: 359.1; found: 359.0.; ESI-HRMS: m/z calcd for $C_{18}H_{16}ClN_2O_2S$ [M-TfO]⁺: 359.0616; found: 359.0616.

1-(N-(3-chlorophenyl)-4-methylphenylsulfonamido)pyridin-1-i-um trifluoromethanesulfonate (3ja). yellow solid (183 mg, 0.36 mmol, 72%). ¹H NMR (400 MHz, METHANOL-D3) δ 9.40 (dd, J = 4.2, 2.5 Hz, 2H), 8.85 (t, J = 7.8 Hz, 1H), 8.27 (t, J = 7.5 Hz, 1H), 7.81 (t, J = 2.0 Hz, 1H), 7.73 (d, J = 8.4 Hz, 2H), 7.66 (ddd, J = 7.9, 2.0, 1.1 Hz, 1H), 7.59 - 7.55 (m, 1H), 7.52 (d, J = 7.8 Hz, 3H), 2.49 (s, 3H); ¹³C NMR (101 MHz, METHANOL-D3) δ 149.92, 148.20, 148.11 (2 \times CH), 138.29, 135.49, 131.51, 131.49, 131.22, 130.84 (2 \times CH), 130.04 (2 \times CH), 129.02 (2 \times CH), 128.78, 126.87, 120.46 (q, J = 318.5 Hz), 20.53; ESI-MS: m/z calcd for $C_{18}H_{16}ClN_2O_2S$ [M-TfO]⁺: 359.1; found: 359.0.; ESI-HRMS: m/z calcd for $C_{18}H_{16}ClN_2O_2S$ [M-TfO]⁺: 359.0616; found: 359.0616.

1-(N-(4-chlorophenyl)-4-methylphenylsulfonamido)pyridin-1-i-um trifluoromethanesulfonate (3ka). yellow solid (214 mg, 0.36 mmol, 84%). ¹H NMR (400 MHz, METHANOL-D3) δ 9.40 (dd, J = 4.2, 2.5 Hz, 2H), 8.85 (t, J = 7.8 Hz, 1H), 8.27 (t, J = 7.5 Hz, 1H), 7.81 (t, J = 2.0 Hz, 1H), 7.73 (d, J = 8.4 Hz, 2H), 7.66 (ddd, J = 7.9, 2.0, 1.1 Hz, 1H), 7.59 - 7.55 (m, 1H), 7.52 (d, J = 7.8 Hz, 3H), 2.49 (s, 3H); ¹³C NMR (101 MHz, METHANOL-D3) δ 149.92, 148.20, 148.11 (2 \times CH), 138.29, 135.49, 131.51, 131.49, 131.22, 130.84 (2 \times CH), 130.04 (2 \times CH), 129.02 (2 \times CH), 128.78, 126.87, 120.46 (q, J = 318.5 Hz), 20.53; ESI-MS: m/z calcd for $C_{18}H_{16}ClN_2O_2S$ [M-TfO]⁺: 359.1; found: 359.0.; ESI-HRMS: m/z calcd for $C_{18}H_{16}ClN_2O_2S$ [M-TfO]⁺: 359.0616; found: 359.0616.

1-(N-(2-bromophenyl)-4-methylphenylsulfonamido)pyridin-1-i-um trifluoromethanesulfonate (3la). yellow solid (199 mg, 0.36 mmol, 72%). ¹H NMR (400 MHz, METHANOL-D3) δ 9.40 (d, J = 6.1 Hz, 2H), 8.81 (t, J = 7.7 Hz, 1H), 8.23 (t, J = 7.1 Hz, 2H), 8.04 (d, J = 7.7 Hz, 1H), 7.71 (t, J = 8.6 Hz, 3H), 7.56 (t, J = 7.4 Hz, 1H), 7.46 (t, J = 8.3 Hz, 3H), 2.45 (s, 3H); ¹³C NMR (76 MHz, METHANOL-D3) δ 149.87, 148.36, 148.05 (2 \times CH), 135.25, 134.80, 133.67, 131.75, 130.88, 130.82 (2 \times CH), 129.75 (2 \times CH), 129.55, 129.22 (2 \times CH), 125.87, 120.45 (q, J = 318.5 Hz), 20.58; ESI-MS: m/z calcd for $C_{18}H_{16}BrN_2O_2S$ [M-TfO]⁺: 403.0; found: 403.0.; ESI-HRMS: m/z calcd for $C_{18}H_{16}BrN_2O_2S$ [M-TfO]⁺: 403.0110; found: 403.0115.

1-(N-(3-bromophenyl)-4-methylphenylsulfonamido)pyridin-1-i-um trifluoromethanesulfonate (3ma). yellow solid (193 mg, 0.35 mmol,

70%). ¹H NMR (400 MHz, METHANOL-D3) δ 9.43 (d, J = 5.6 Hz, 2H), 8.86 (t, J = 7.8 Hz, 1H), 8.27 (t, J = 7.5 Hz, 1H), 7.95 (t, J = 2.0 Hz, 1H), 7.77 - 7.67 (m, 4H), 7.53 (d, J = 8.3 Hz, 2H), 7.46 (t, J = 8.1 Hz, 1H), 2.51 (s, 3H); ¹³C NMR (101 MHz, METHANOL-D3) δ 149.88, 148.15 (2 \times CH, 1 \times C), 138.38, 134.47, 131.67 (2 \times CH), 131.35, 130.80 (2 \times CH), 130.00 (2 \times CH), 129.02 (2 \times CH), 127.28, 123.04, 120.48 (q, J = 318.4 Hz), 20.49; ESI-MS: m/z calcd for $C_{18}H_{16}BrN_2O_2S$ [M-TfO]⁺: 403.0; found: 403.0.; ESI-HRMS: m/z calcd for $C_{18}H_{16}BrN_2O_2S$ [M-TfO]⁺: 403.0110; found: 403.0111.

1-(N-(4-bromophenyl)-4-methylphenylsulfonamido)pyridin-1-i-um trifluoromethanesulfonate (3na). yellow solid (177 mg, 0.32 mmol, 64%). ¹H NMR (301 MHz, DMSO-D6) δ 9.61 (d, J = 5.8 Hz, 2H), 8.90 (t, J = 7.8 Hz, 1H), 8.35 (t, J = 7.3 Hz, 1H), 7.80 - 7.70 (m, 6H), 7.54 (d, J = 8.3 Hz, 2H), 2.47 (s, 3H); ¹³C NMR (76 MHz, DMSO-D6) δ 150.68, 148.72 (2 \times CH), 147.78, 136.66, 133.86 (2 \times CH), 131.68, 131.47 (2 \times CH), 131.43 (2 \times CH), 130.80 (2 \times CH), 129.41 (2 \times CH), 125.47, 121.22 (q, J = 322.2 Hz), 21.81; ESI-MS: m/z calcd for $C_{18}H_{16}BrN_2O_2S$ [M-TfO]⁺: 403.0; found: 413.0.; ESI-HRMS: m/z calcd for $C_{18}H_{16}BrN_2O_2S$ [M-TfO]⁺: 403.0110; found: 403.0113.

1-(4-methyl-N-(4-(trifluoromethoxy)phenyl)phenylsulfonamido)pyridin-1-i-um trifluoromethanesulfonate (3oa). yellow solid (195 mg, 0.32 mmol, 70%). ¹H NMR (400 MHz, METHANOL-D3) δ 9.39 (d, J = 5.7 Hz, 2H), 8.85 (t, J = 7.8 Hz, 1H), 8.27 (t, J = 7.3 Hz, 1H), 7.84 (d, J = 9.0 Hz, 2H), 7.73 (d, J = 8.4 Hz, 2H), 7.51 (d, J = 8.2 Hz, 2H), 7.42 (d, J = 8.6 Hz, 2H), 2.49 (s, 3H); ¹³C NMR (101 MHz, METHANOL-D3) δ 150.80, 149.86, 148.16, 148.07 (2 \times CH), 135.76, 131.23, 130.90 (2 \times CH), 130.84 (2 \times CH), 130.04 (2 \times CH), 129.00, 122.38, 120.42 (q, J = 318.5 Hz), 120.31 (q, J = 257.4 Hz), 20.51; ESI-MS: m/z calcd for $C_{19}H_{16}F_3N_2O_3S$ [M-TfO]⁺: 409.1; found: 409.0; ESI-HRMS: m/z calcd for $C_{19}H_{16}F_3N_2O_3S$ [M-TfO]⁺: 409.0828; found: 409.0829.

1-(4-methyl-N-(4-(trifluoromethyl)phenyl)phenylsulfonamido)pyridin-1-i-um trifluoromethanesulfonate (3pa). yellow solid (177 mg, 0.32 mmol, 65%). ¹H NMR (301 MHz, DMSO-D6) δ 9.63 (d, J = 5.9 Hz, 2H), 8.93 (t, J = 7.6 Hz, 1H), 8.38 (t, J = 7.0 Hz, 2H), 7.94 (s, 4H), 7.80 (d, J = 8.2 Hz, 2H), 7.55 (d, J = 8.1 Hz, 2H), 2.47 (s, 3H); ¹³C NMR (76 MHz, DMSO-D6) δ 150.93, 149.07 (2 \times CH), 147.97, 140.94, 131.66, 131.57 (2 \times CH), 131.03 (q, J = 31.7 Hz), 130.92, 129.48 (2 \times CH), 128.78 (2 \times CH), 127.96 (q, J = 3.2 Hz), 124.01 (q, J = 272.7 Hz), 121.22 (q, J = 322.1 Hz), 21.83; ESI-MS: m/z calcd for $C_{19}H_{16}F_3N_2O_2S$ [M-TfO]⁺: 393.1; found: 393.0; ESI-HRMS: m/z calcd for $C_{19}H_{16}F_3N_2O_2S$ [M-TfO]⁺: 393.0879; found: 393.0882.

2-methyl-1-(4-methyl-N-phenylphenylsulfonamido)pyridin-1-i-um trifluoromethanesulfonate (3ab). yellow solid (108 mg, 0.23 mmol, 45%). ¹H NMR (400 MHz, METHANOL-D3): δ 9.19 (d, J = 6.3 Hz, 1H), 8.75 (t, J = 7.7 Hz, 1H), 8.29 (d, J = 7.8 Hz, 1H), 8.16 (t, J = 6.7 Hz, 1H), 7.73 (d, J = 8.3 Hz, 2H), 7.64 (dd, J = 6.6, 3.1 Hz, 2H), 7.60 - 7.50 (m, 5H), 3.05 (s, 3H), 2.54 (s, 3H); ¹³C NMR (101 MHz, METHANOL-D3): δ 161.02, 148.96, 148.05, 147.37, 136.86, 131.87, 131.59, 130.82 (2 \times CH), 130.47, 130.35 (2 \times CH), 128.93 (2 \times CH), 127.48, 126.86 (2 \times CH), 120.51 (q, J = 318.4 Hz), 20.53, 19.33; ESI-MS: m/z calcd for $C_{19}H_{19}N_2O_2S$ [M-TfO]⁺: 339.1; found: 339.0; ESI-HRMS: m/z calcd for $C_{19}H_{19}N_2O_2S$ [M-TfO]⁺: 339.1162; found: 339.1162.

1-(N-(4-chlorophenyl)-4-methylphenylsulfonamido)-2-methylpyridin-1-i-um trifluoromethanesulfonate (3kb). yellow solid (240 mg, 0.46 mmol, 92%). ¹H NMR (301 MHz, METHANOL-D3): δ 9.16 (dd, J = 6.6, 1.1 Hz, 1H), 8.75 (td, J = 7.9, 1.2 Hz, 1H), 8.29 (dd, J = 8.1, 1.5 Hz, 1H), 8.14 (td, J = 7.7, 1.6 Hz, 1H), 7.75 (d, J = 8.4 Hz, 2H), 7.67 - 7.59 (m, 2H), 7.57 (t, J = 2.4 Hz, 2H), 7.55 (d, J = 2.7 Hz, 2H), 3.03 (s, 3H), 2.54 (s, 3H); ¹³C NMR (76 MHz, METHANOL-D3): δ 161.15, 149.05, 148.24, 147.26, 136.44,

135.35, 131.67, 131.61, 130.87 (2×CH), 130.35 (2×CH), 128.97 (2×CH), 128.54 (2×CH), 127.49, 124.86 (q, $J = 346.1$ Hz), 20.48, 19.25; ESI-MS: m/z calcd for $C_{19}H_{18}ClN_2O_2S$ [M-TfO]⁺: 373.0; found: 372.9; ESI-HRMS: m/z calcd for $C_{19}H_{18}ClN_2O_2S$ [M-TfO]⁺: 373.0772; found: 373.0770.

X-ray crystal structure analysis of compound 3kb. Single crystals suitable for X-ray analysis were obtained by slow evaporation of its solution in CH₃OH. The crystal structure has been deposited at the Cambridge Crystallographic Data Centre and allocated the deposition number: **CCDC** 1008472. Formula: C₂₀H₁₈ClF₃N₂O₅S, $M = 522.95$, colourless crystal, 0.20 x 0.14 x 0.13 mm, $a = 8.6089(17)$, $b = 8.8898(18)$, $c = 15.632(3)$ Å, $\alpha = 98.35(3)$, $\beta = 96.13(3)$, $\gamma = 104.16(3)$, $V = 1135.0(4)$ Å³, $\rho_{calc} = 1.530$ g/cm⁻³, $\mu = 0.412$ mm⁻¹, $Z = 2$, Triclinic, space group *P-1*, $\lambda = 0.71073$ Å, $T = 173(2)$ K. Data completeness = 0.987, Theta (max) = 27.46, R (reflections) = 0.0884, wR2 (reflections) = 0.2084 (5129).

3-methyl-1-(4-methyl-N-(*p*-tolyl)phenylsulfonamido)pyridin-1-iium trifluoromethanesulfonate (3dc). yellow solid (221 mg, 0.44 mmol, 88%). ¹H NMR (301 MHz, METHANOL-D3) δ 9.28 (s, 1H), 9.19 (d, $J = 6.1$ Hz, 1H), 8.64 (d, $J = 7.9$ Hz, 1H), 8.11 (dd, $J = 7.8$, 6.6 Hz, 1H), 7.72 (d, $J = 8.4$ Hz, 2H), 7.58 (d, $J = 8.4$ Hz, 2H), 7.49 (d, $J = 8.2$ Hz, 2H), 7.30 (d, $J = 8.2$ Hz, 2H), 2.59 (s, 3H), 2.48 (s, 3H), 2.35 (s, 3H); ¹³C NMR (76 MHz, METHANOL-D3) δ 150.04, 147.67, 147.20, 144.88, 142.41, 142.32, 134.92, 131.79, 130.78 (2×CH), 130.61 (2×CH), 129.03 (2×CH), 128.83, 128.66 (2×CH), 120.52 (q, $J = 318.4$ Hz), 20.50, 19.93, 17.08; ESI-MS: m/z calcd for C₂₀H₂₁N₂O₂S [M-TfO]⁺: 353.1318; found: 353.1; ESI-HRMS: m/z calcd for C₂₀H₂₁N₂O₂S [M-TfO]⁺: 353.1318; found: 353.1319.

1-(*N*-(4-chlorophenyl)-4-methylphenylsulfonamido)-4-methylpyridin-1-iium trifluoromethanesulfonate (3kd). yellow solid (230 mg, 0.44 mmol, 88%). ¹H NMR (301 MHz, METHANOL-D3): 8.87 (d, $J = 6.8$ Hz, 2H), 8.06 (d, $J = 6.6$ Hz, 2H), 7.75 (d, $J = 8.2$ Hz, 2H), 7.36 (d, $J = 8.9$ Hz, 2H), 7.29 (d, $J = 7.9$ Hz, 2H), 6.83 (d, $J = 8.9$ Hz, 2H), 2.77 (s, 3H), 2.40 (s, 3H); ¹³C NMR (76 MHz, METHANOL-D3): δ 161.75, 145.37 (2×CH), 143.89, 141.22, 141.04, 129.96 (2×CH), 129.59 (2×CH), 129.12, 128.67, 125.66 (2×CH), 120.36 (q, $J = 318.4$ Hz), 117.09 (2×CH), 21.04, 20.03; ESI-HRMS: m/z calcd for C₁₉H₁₈ClN₂O₂S [M-TfO]⁺: 373.0772; found: 373.0772.

3-ethoxy-1-(4-methyl-N-(*p*-tolyl)phenylsulfonamido)pyridin-1-iium trifluoromethanesulfonate (3de)⁸. yellow solid (226 mg, 0.44 mmol, 85%). ¹H NMR (400 MHz, METHANOL-D4) δ 9.07 - 9.05 (m, 1H), 8.94- 8.90 (m, 1H), 8.38 - 8.32 (m, 1H), 8.09 (dd, $J = 8.9$, 6.3 Hz, 1H), 7.74 - 7.69 (m, 2H), 7.63 - 7.59 (m, 2H), 7.47 (d, $J = 8.1$ Hz, 2H), 7.29 (t, $J = 7.5$ Hz, 2H), 4.30 (dq, $J = 13.9$, 7.0 Hz, 2H), 2.46 (s, 3H), 2.32 (s, 3H), 1.44 (t, $J = 7.0$ Hz, 3H); ¹³C NMR (101 MHz, METHANOL-D4) δ 160.6, 148.9, 143.5, 140.5, 137.1, 136.1, 135.5, 132.8, 132.0, 131.9, 130.7, 130.5, 130.3, 130.0, 129.8, 129.1, 128.2, 68.4, 21.8, 21.2, 14.4.

3-chloro-1-(*N*-(2-fluorophenyl)-4-methylphenylsulfonamido)pyridin-1-iium trifluoromethanesulfonate (3ff). yellow solid (177 mg, 0.34 mmol, 67%). ¹H NMR (400 MHz, METHANOL-D3) δ 9.35 (s, 1H), 8.93 (d, $J = 6.1$ Hz, 1H), 8.59 (d, $J = 8.3$ Hz, 1H), 7.93 (t, $J = 7.3$ Hz, 1H), 7.60 (t, $J = 7.6$ Hz, 1H), 7.41 (d, $J = 6.2$ Hz, 2H), 7.34 - 7.25 (m, 1H), 7.19 (d, $J = 6.0$ Hz, 2H), 7.09 - 6.94 (m, 2H), 2.17 (s, 3H); ¹³C NMR (101 MHz, METHANOL-D3) δ 159.27 (d, J' = 254.0 Hz), 149.61, 147.80, 147.27, 146.75 (d, J'' = 1.1 Hz), 137.07, 134.23 (d, J^3 = 8.4 Hz), 131.34, 131.20, 130.52 (2×CH), 129.83, 128.56 (2×CH), 125.50 (d, J^3 = 2.6 Hz), 123.71 (d, J^2 = 12.7 Hz), 120.34 (q, $J = 318.3$ Hz), 116.98 (d, J^2 = 20.0 Hz), 20.23; ESI-MS: m/z calcd for C₁₈H₁₅ClFN₂O₂S [M-TfO]⁺: 377.1; found: 376.9; ESI-HRMS: m/z calcd for C₁₈H₁₅ClFN₂O₂S [M-TfO]⁺: 377.0521; found: 377.0518.

1-(*N*-(4-bromophenyl)-4-methylphenylsulfonamido)-3-chloropyridin-1-iium trifluoromethanesulfonate (3nf). yellow solid (217 mg, 0.37 mmol, 74%). ¹H NMR (400 MHz, METHANOL-D3) δ 9.81 (s, 1H), 9.38 (d, $J = 8.2$ Hz, 1H), 8.98 (d, $J = 7.3$ Hz, 1H), 8.27 (dd, $J = 8.5$, 6.4 Hz, 1H), 7.75 (d, $J = 8.4$ Hz, 2H), 7.69 - 7.62 (m, 4H), 7.52 (d, $J = 8.3$ Hz, 2H), 2.50 (s, 3H); ¹³C NMR (101 MHz, METHANOL-D3) δ 149.71, 148.23, 147.68, 146.62, 137.44, 136.12, 133.48 (2×CH), 131.09, 130.86 (2×CH), 130.67 (2×CH), 130.12, 129.14 (2×CH), 125.75, 120.49 (q, $J = 318.6$ Hz), 20.57; ESI-MS: m/z calcd for C₁₈H₁₅BrClN₂O₂S [M-TfO]⁺: 437.0; found: 437.1; ESI-HRMS: m/z calcd for C₁₈H₁₅BrClN₂O₂S [M-TfO]⁺: 436.9721; found: 436.9719.

3-chloro-1-(4-methyl-N-(4-(trifluoromethoxy)phenyl)-phenylsulfonamido)pyridin-1-iium trifluoromethanesulfonate (3of). yellow solid (221 mg, 0.39 mmol, 78%). ¹H NMR (400 MHz, METHANOL-D3) δ 9.72 (s, 1H), 9.27 (d, $J = 6.0$ Hz, 1H), 8.80 (d, $J = 8.3$ Hz, 1H), 8.13 (d, $J = 7.2$ Hz, 1H), 7.71 (d, $J = 8.8$ Hz, 2H), 7.63 (d, $J = 8.2$ Hz, 2H), 7.39 (d, $J = 8.0$ Hz, 2H), 7.30 (d, $J = 8.5$ Hz, 2H), 2.37 (s, 3H); ¹³C NMR (101 MHz, DMSO-D6) δ 150.38, 150.29, 148.22, 147.70, 147.58, 136.85, 135.75, 132.36 (2×CH), 131.71, 131.39 (2×CH), 130.88, 129.41 (2×CH), 123.00 (2×CH), 121.13 (d, $J = 322.6$ Hz), 120.30 (q, $J = 257.9$ Hz), 21.74; ESI-MS: m/z calcd for C₁₉H₁₅ClF₃N₂O₃S [M-TfO]⁺: 443.0; found: 443.0; ESI-HRMS: m/z calcd for C₁₉H₁₅ClF₃N₂O₃S [M-TfO]⁺: 443.0439; found: 443.0438.

3-chloro-1-(4-methyl-N-(4-(trifluoromethyl)phenyl)-phenylsulfonamido)pyridin-1-iium trifluoromethanesulfonate (3pf). yellow solid (179 mg, 0.31 mmol, 62%). ¹H NMR (400 MHz, DMSO-D6) δ 10.09 (s, 1H), 9.56 (d, $J = 5.9$ Hz, 1H), 9.03 (d, $J = 8.2$ Hz, 1H), 8.35 (t, $J = 7.2$ Hz, 1H), 7.90 (dd, $J = 20.1$, 8.5 Hz, 4H), 7.75 (d, $J = 8.0$ Hz, 2H), 7.49 (d, $J = 8.0$ Hz, 2H), 2.41 (s, 3H); ¹³C NMR (101 MHz, DMSO-D6) δ 150.55, 148.46, 147.93, 147.85, 140.60, 136.98, 131.65, 131.48, 131.24 (q, $J = 32.6$ Hz), 130.98, 129.53 (4×CH), 127.78 (q, $J = 3.1$ Hz), 123.99 (q, $J = 272.7$ Hz), 121.18 (q, $J = 322.2$ Hz), 21.79; ESI-MS: m/z calcd for C₁₉H₁₅ClF₃N₂O₂S [M-TfO]⁺: 427.0; found: 427.0.; ESI-HRMS: m/z calcd for C₁₉H₁₅ClF₃N₂O₂S [M-TfO]⁺: 427.0489; found: 427.0487.

3-chloro-1-(*N*-(4-(methoxycarbonyl)phenyl)-4-methylphenylsulfonamido)pyridin-1-iium trifluoromethanesulfonate (3gf). yellow solid (210 mg, 0.37 mmol, 74%). ¹H NMR (400 MHz, METHANOL-D3) δ 9.77 (s, 1H), 9.32 (d, $J = 6.1$ Hz, 1H), 8.89 (d, $J = 8.3$ Hz, 1H), 8.23 (t, $J = 7.3$ Hz, 1H), 8.02 (d, $J = 8.5$ Hz, 2H), 7.72 (dd, $J = 8.3$, 1.2 Hz, 4H), 7.46 (d, $J = 8.1$ Hz, 2H), 3.83 (s, 3H), 2.43 (s, 3H); ¹³C NMR (101 MHz, METHANOL-D3) δ 165.49, 149.93, 148.31, 147.92, 146.92, 140.84, 137.51, 132.06, 131.11 (2×CH), 130.88 (2×CH), 130.17, 129.13 (2×CH), 127.60 (2×CH), 120.37 (q, $J = 318.2$ Hz), 51.79, 20.52; ESI-MS: m/z calcd for C₂₀H₁₈ClN₂O₄S [M-TfO]⁺: 417.1; found: 417.1; ESI-HRMS: m/z calcd for C₂₀H₁₈ClN₂O₄S [M-TfO]⁺: 417.0670; found: 417.0670.

1-(*N*-(*p*-tolyl)phenylsulfonamido)pyridin-1-iium trifluoromethanesulfonate (3dg)⁸. yellow solid (209 mg, 0.44 mmol, 88%). ¹H NMR (400 MHz, METHANOL-D3) δ 9.44 (dd, $J = 5.3$, 1.4 Hz, 2H), 8.84 (td, $J = 7.8$, 1.2 Hz, 1H), 8.27 (t, $J = 7.5$ Hz, 1H), 7.90 - 7.83 (m, 1H), 7.73 - 7.65 (m, 2H), 7.58 (d, $J = 8.4$ Hz, 2H), 7.32 (d, $J = 8.4$ Hz, 2H), 2.36 (s, 3H); ¹³C NMR (101 MHz, METHANOL-D3) δ: 149.64, 147.96 (2×CH), 142.59, 135.79, 134.84, 134.70, 130.86 (2×CH), 130.13 (2×CH), 129.95 (2×CH), 128.95 (2×CH), 128.77 (2×CH), 120.48 (q, $J = 318.6$ Hz), 19.93; ESI-MS: m/z calcd for C₁₈H₁₇N₂O₂S [M-TfO]⁺: 325.1; found: 325.1; ESI-HRMS: m/z calcd for C₁₈H₁₇N₂O₂S [M-TfO]⁺: 325.1005; found: 325.1006.

1-(2-(4-methylphenylsulfonamido)phenyl)pyridin-1-iium hexafluorophosphate(V) (4aa)⁸. yellow solid (106 mg, 0.23 mmol,

45%). ¹H NMR (301 MHz, DMSO-D6) δ 8.99 (dd, *J* = 6.6, 1.2 Hz, 2H), 8.68 (tt, *J* = 8.0, 1.3 Hz, 1H), 8.20 (dd, *J* = 7.7, 6.7 Hz, 2H), 7.51 (d, *J* = 8.1 Hz, 2H), 7.35 (dd, *J* = 7.8, 1.2 Hz, 1H), 7.25 - 7.11 (m, 4H), 6.71 (t, *J* = 6.9 Hz, 1H), 2.30 (s, 3H); ¹³C NMR (76 MHz, DMSO-D6): δ 147.22 (2×CH), 146.14, 144.18, 143.71, 139.95, 134.81, 131.43, 129.25 (2×CH), 127.70 (2×CH), 126.59 (2×CH), 125.95, 121.33, 116.73, 21.37; ESI-MS: m/z calcd for C₁₈H₁₇N₂O₂S [M-PF₆]⁺: 325.1; found: 325.1; ESI-HRMS: m/z calcd for C₁₈H₁₇N₂O₂S [M-PF₆]⁺: 325.1005; found: 325.1004.

1-(3-methyl-2-(4-methylphenylsulfonamido)phenyl)pyridin-1-i um trifluoromethanesulfonate (4ba). yellow solid (142 mg, 0.29 mmol, 58%). ¹H NMR (400 MHz, METHANOL-D3): δ 9.04 (d, *J* = 5.8 Hz, 2H), 8.70 (t, *J* = 7.8 Hz, 1H), 8.17 (d, *J* = 6.9 Hz, 1H), 7.58 (dd, *J* = 6.1, 3.2 Hz, 1H), 7.53 - 7.44 (m, 2H), 7.42 (d, *J* = 8.2 Hz, 2H), 7.28 (d, *J* = 8.2 Hz, 2H), 2.39 (s, 3H), 1.78 (s, 3H); ¹³C NMR (76 MHz, METHANOL-D3): δ 146.83 (2×CH), 146.77, 144.67, 141.96, 139.85, 137.07, 134.14, 129.75 (2×CH), 129.04, 128.61, 127.33 (2×CH), 126.76 (2×CH), 124.87, 120.44 (q, *J* = 318.2 Hz), 20.21, 16.35; ESI-MS: m/z calcd for C₁₉H₁₉N₂O₂S [M-TfO]⁺: 339.1; found: 339.0; ESI-HRMS: m/z calcd for C₁₉H₁₉N₂O₂S [M-TfO]⁺: 339.1162; found: 339.1159.

1-(5-methyl-2-(4-methylphenylsulfonamido)phenyl)pyridin-1-i um trifluoromethanesulfonate (4da). yellow solid (188 mg, 0.39 mmol, 77%). ¹H NMR (301 MHz, METHANOL-D3): δ 9.00 (d, *J* = 6.3 Hz, 2H), 8.77 (t, *J* = 7.8 Hz, 1H), 8.24 (t, *J* = 6.7 Hz, 2H), 7.58 (s, 1H), 7.49 (d, *J* = 8.1 Hz, 2H), 7.34 (d, *J* = 7.7 Hz, 3H), 6.83 (d, *J* = 8.2 Hz, 1H), 3.39 (s, 3H), 2.44 (s, 3H); ¹³C NMR (76 MHz, METHANOL-D3): δ 146.74, 146.57 (2×CH), 144.31, 139.77, 139.60, 135.85, 132.67, 129.55 (2×CH), 128.73, 128.65, 127.48 (2×CH), 127.34, 127.07 (2×CH), 120.37 (q, *J* = 318.3 Hz), 20.23, 19.54; ESI-MS: m/z calcd for C₁₉H₁₉N₂O₂S [M-TfO]⁺: 339.1; found: 339.0; ESI-HRMS: m/z calcd for C₁₉H₁₉N₂O₂S [M-TfO]⁺: 339.1162; found: 339.1162.

X-ray crystal structure analysis of compound 4da. Single crystals suitable for X-ray analysis were obtained by slow evaporation of its solution in CH₃OH. The crystal structure has been deposited at the Cambridge Crystallographic Data Centre and allocated the deposition number: CCDC 1008474. Formula: C₁₉H₁₉F₆N₂O₂PS, *M* = 484.40, colourless crystal, 0.48 x 0.43 x 0.26 mm, *a* = 15.338(3), *b* = 10.040(2), *c* = 14.189(3) Å, α = 90, β = 94.34(3), γ = 90, *V* = 2178.7(8) Å³, ρ_{calc} = 1.477 g cm⁻³, μ = 0.291 mm⁻¹, *Z* = 4, Monoclinic, space group P2(1)*c*, λ = 0.71073 Å, *T* = 173(2) K. Data completeness = 0.997, Theta (max) = 27.48, R (reflections) = 0.0811, wR2 (reflections) = 0.2007 (4971).

1-(3,5-dimethyl-2-(4-methylphenylsulfonamido)-phenyl)pyridin-1-i um trifluoromethanesulfonate (4ea). yellow solid (121 mg, 0.24 mmol, 48%). ¹H NMR (400 MHz, METHANOL-D3): δ 9.06 (d, *J* = 5.9 Hz, 2H), 8.75 (t, *J* = 7.8 Hz, 1H), 8.22 (t, *J* = 7.2 Hz, 2H), 7.53 - 7.41 (m, 3H), 7.34 (d, *J* = 8.3 Hz, 3H), 2.45 (s, 6H), 1.75 (s, 3H); ¹³C NMR (101 MHz, METHANOL-D3): δ 146.76 (2×CH), 146.64, 144.55, 141.69, 140.06, 139.41, 137.11, 134.58, 129.72 (2×CH), 127.26 (2×CH), 126.78 (2×CH), 125.80, 125.30, 120.48 (q, *J* = 318.7 Hz), 20.20, 19.58, 16.28; ESI-MS: m/z calcd for C₂₀H₂₁N₂O₂S [M-TfO]⁺: 353.1; found: 353.1; ESI-HRMS: m/z calcd for C₂₀H₂₁N₂O₂S [M-TfO]⁺: 353.1312; found: 353.1312.

1-(5-fluoro-2-(4-methylphenylsulfonamido)phenyl)pyridin-1-i um trifluoromethanesulfonate (4ha). yellow solid (182 mg, 0.37 mmol, 74%). ¹H NMR (301 MHz, METHANOL-D3): δ 9.03 (d, *J* = 5.7 Hz, 2H), 8.75 (t, *J* = 7.9 Hz, 1H), 8.21 (dd, *J* = 7.5, 6.8 Hz, 2H), 7.67 (dd, *J* = 8.1, 2.9 Hz, 1H), 7.44 (d, *J* = 8.3 Hz, 2H), 7.34 - 7.23 (m, 3H), 6.86 (dd, *J* = 8.9, 5.2 Hz, 1H), 2.35 (d, *J* = 17.5 Hz, 3H); ¹³C NMR (76 MHz, METHANOL-D3): δ 162.50 (d, *J'* = 251.1 Hz), 148.67, 147.98 (2×CH), 145.95, 142.16 (d, *J*' = 10.6 Hz), 136.53, 132.33, 132.21, 130.91 (2×CH), 128.85 (2×CH), 128.45 (2×CH), 121.69 (q,

J = 318.3 Hz), 120.39 (d, *J*' = 22.3 Hz), 116.37 (d, *J*' = 27.6 Hz), 21.47; ESI-MS: m/z calcd for C₁₈H₁₆FN₂O₂S [M-TfO]⁺: 343.1; found: 343.1; ESI-HRMS: m/z calcd for C₁₈H₁₆FN₂O₂S [M-TfO]⁺: 343.0911; found: 343.0907.

1-(5-chloro-2-(4-methylphenylsulfonamido)phenyl)pyridin-1-i um trifluoromethanesulfonate (4ka). yellow solid (160 mg, 0.32 mmol, 63%). ¹H NMR (301 MHz, METHANOL-D3): δ 8.92 (d, *J* = 5.8 Hz, 2H), 8.75 (t, *J* = 7.9 Hz, 1H), 8.21 (t, *J* = 6.8 Hz, 1H), 7.73 (d, *J* = 2.4 Hz, 1H), 7.55 (d, *J* = 8.2 Hz, 2H), 7.46 (dd, *J* = 8.7, 2.4 Hz, 1H), 7.32 (d, *J* = 8.0 Hz, 2H), 7.16 (d, *J* = 8.8 Hz, 1H), 2.43 (s, 3H); ¹³C NMR (76 MHz, METHANOL-D3): δ 146.76, 146.49 (2×CH), 143.21, 141.00, 138.11, 131.78, 129.41 (2×CH), 129.13, 128.68 (2×CH), 127.53 (2×CH), 126.58, 126.44, 125.67, 120.37 (q, *J* = 318.2 Hz), 20.16; ESI-MS: m/z calcd for C₁₈H₁₆ClN₂O₂S [M-TfO]⁺: 359.1; found: 359.0; ESI-HRMS: m/z calcd for C₁₈H₁₆ClN₂O₂S [M-TfO]⁺: 359.0616; found: 359.0614.

2-methyl-1-(5-methyl-2-(4-methylphenylsulfonamido)-phenyl)pyridin-1-i um trifluoromethanesulfonate (4db). yellow solid (196 mg, 0.39 mmol, 78%). ¹H NMR (400 MHz, METHANOL-D3): δ 8.80 (d, *J* = 6.0 Hz, 1H), 8.64 (t, *J* = 7.8 Hz, 1H), 8.16 (d, *J* = 8.0 Hz, 1H), 8.03 (t, *J* = 6.8 Hz, 1H), 7.56 (d, *J* = 8.1 Hz, 3H), 7.39 (d, *J* = 8.1 Hz, 3H), 6.78 (d, *J* = 8.2 Hz, 1H), 2.62 (s, 3H), 2.44 (dd, *J* = 13.6, 2.1 Hz, 6H); ¹³C NMR (101 MHz, METHANOL-D3): δ 157.08, 147.57, 146.84, 144.65, 140.61, 135.72, 132.89, 129.66 (2×CH), 129.28, 128.98, 128.43, 127.85, 127.23 (2×CH), 126.42, 124.68, 120.48 (q, *J* = 318.6 Hz), 20.25, 20.11, 19.58; ESI-MS: m/z calcd for C₂₀H₂₁N₂O₂S [M-TfO]⁺: 353.1; found: 353.1; ESI-HRMS: m/z calcd for C₂₀H₂₁N₂O₂S [M-TfO]⁺: 353.1318; found: 353.1315.

3-methyl-1-(5-methyl-2-(4-methylphenylsulfonamido)-phenyl)pyridin-1-i um trifluoromethanesulfonate (4dc). yellow solid (191 mg, 0.38 mmol, 76%). ¹H NMR (301 MHz, METHANOL-D3): δ 8.82 (s, 1H), 8.74 (d, *J* = 3.5 Hz, 1H), 8.53 (d, *J* = 7.9 Hz, 1H), 8.04 (dd, *J* = 7.1, 4.3 Hz, 1H), 7.52 (s, 1H), 7.44 (d, *J* = 7.6 Hz, 2H), 7.29 (d, *J* = 7.1 Hz, 3H), 6.78 (s, 1H), 2.61 (s, 3H), 2.41 (s, 6H); ¹³C NMR (76 MHz, METHANOL-D3): δ 147.03 (2×CH), 146.19, 144.01, 143.78, 139.57, 139.19, 138.86, 136.65, 132.40, 129.41 (2×CH), 128.45, 127.02 (2×CH), 126.66 (2×CH), 120.49 (q, *J* = 318.7 Hz), 20.16, 19.39, 17.18; ESI-MS: m/z calcd for C₂₀H₂₁N₂O₂S [M-TfO]⁺: 353.13; found: 353.1; ESI-HRMS: m/z calcd for C₂₀H₂₁N₂O₂S [M-TfO]⁺: 353.1318; found: 353.1319.

4-methyl-1-(5-methyl-2-(4-methylphenylsulfonamido)-phenyl)pyridin-1-i um trifluoromethanesulfonate (4dd). yellow solid (201 mg, 0.4 mmol, 80%). ¹H NMR (400 MHz, METHANOL-D3): δ 8.81 (d, *J* = 6.8 Hz, 2H), 8.04 (d, *J* = 6.4 Hz, 2H), 7.55 (d, *J* = 1.2 Hz, 1H), 7.49 (d, *J* = 8.3 Hz, 2H), 7.33 (dd, *J* = 6.0, 5.4 Hz, 3H), 6.78 (d, *J* = 8.2 Hz, 1H), 2.79 (s, 3H), 2.44 (s, 6H); ¹³C NMR (101 MHz, METHANOL-D3): δ 145.40 (2×CH), 144.40, 140.00, 139.72, 135.78, 132.48, 129.51 (3×CH), 128.84, 128.40, 128.36, 127.87, 127.43, 127.14 (2×CH), 120.49 (q, *J* = 318.5 Hz), 20.21, 20.06, 19.53; ESI-MS: m/z calcd for C₂₀H₂₁N₂O₂S [M-TfO]⁺: 353.1; found: 353.1; ESI-HRMS: m/z calcd for C₂₀H₂₁N₂O₂S [M-TfO]⁺: 353.1318; found: 353.1319.

3-ethoxy-1-(5-methyl-2-(4-methylphenylsulfonamido)-phenyl)pyridin-1-i um hexafluorophosphate(V) (4de)⁸. yellow solid (193 mg, 0.37 mmol, 73%). ¹H NMR (301 MHz, METHANOL-D3): δ 8.68 (s, 1H), 8.50 (d, *J* = 5.8 Hz, 1H), 8.27 (dt, *J* = 16.8, 8.4 Hz, 1H), 8.07 (dd, *J* = 8.8, 5.8 Hz, 1H), 7.59 - 7.44 (m, 3H), 7.33 (d, *J* = 8.0 Hz, 3H), 6.89 (d, *J* = 8.1 Hz, 1H), 4.36 (q, *J* = 7.0 Hz, 2H), 2.41 (d, *J* = 16.8 Hz, 6H), 1.54 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (76 MHz, METHANOL-D3): δ 157.79, 143.89, 139.53, 138.71, 138.59, 136.84, 134.40, 132.49, 131.88, 129.75, 129.46 (2×CH), 128.24, 127.66, 127.13, 126.93 (2×CH), 66.37, 20.19, 19.45, 13.32; ESI-MS: m/z calcd for C₂₁H₂₃N₂O₃S [M-PF₆]⁺: 383.1; found: 383.1; ESI-

HRMS: m/z calcd for $C_{21}H_{23}N_2O_3S$ [M-PF₆⁻]: 383.1424; found: 383.1420.

3-fluoro-1-(2-(4-methylphenylsulfonamido)phenyl)pyridin-1-i-um trifluoromethanesulfonate (4ah). yellow solid (194 mg, 0.4 mmol, 79%). ¹H NMR (301 MHz, METHANOL-D3): δ 9.04 (d, J = 6.1 Hz, 1H), 8.76 (dd, J = 16.7, 8.5 Hz, 1H), 8.35 (dt, J = 8.9, 5.7 Hz, 1H), 7.81 (dd, J = 8.8, 3.8 Hz, 1H), 7.67 - 7.42 (m, 5H), 7.37 (t, J = 8.6 Hz, 2H), 7.04 - 6.94 (m, 1H), 2.46 (s, 3H); ¹³C NMR (76 MHz, METHANOL-D3): δ 160.34 (d, J' = 255.4 Hz), 144.62, 144.06 (d, J' = 3.4 Hz), 139.40, 135.37, 134.35 (d, J' = 18.6 Hz), 132.58, 131.11, 129.81, 129.58 (2 \times CH), 128.93 (d, J' = 8.1 Hz), 128.77 (d, J' = 7.4 Hz), 127.77, 127.16 (2 \times CH), 127.08, 120.44 (q, J = 318.5 Hz), 20.20; ESI-MS: m/z calcd for $C_{18}H_{16}FN_2O_2S$ [M-TFO⁻]⁺: 343.1; found: 343.0; ESI-HRMS: m/z calcd for $C_{18}H_{16}FN_2O_2S$ [M-TFO⁻]⁺: 343.0911; found: 343.0911.

3-fluoro-1-(5-fluoro-2-(4-methylphenylsulfonamido)-phenyl)pyridin-1-i-um trifluoromethanesulfonate (4hh). yellow solid (217 mg, 0.4 mmol, 85%). ¹H NMR (600 MHz, METHANOL-D3) δ 9.54 (s, 1H), 9.13 (d, J = 5.6 Hz, 1H), 8.82 (t, J = 7.9 Hz, 1H), 8.42 (dt, J = 8.9, 5.4 Hz, 1H), 7.84 (dd, J = 7.6, 2.0 Hz, 1H), 7.56 (d, J = 8.0 Hz, 2H), 7.43 (t, J = 8.2 Hz, 3H), 6.97 (dd, J = 8.6, 5.0 Hz, 1H), 2.50 (s, 3H); ¹³C NMR (151 MHz, METHANOL-D3): δ 162.66 (d, J' = 251.8 Hz), 161.64 (d, J' = 256.2 Hz), 146.21, 145.43 (d, J' = 2.3 Hz), 141.68 (d, J' = 9.0 Hz), 138.47 (d, J' = 38.6 Hz), 136.24, 136.14 (d, J' = 3.0 Hz), 132.57 (d, J' = 8.4 Hz), 130.96 (2 \times CH), 130.35 (d, J' = 7.4 Hz), 128.53 (2 \times CH), 128.25 (d, J' = 2.0 Hz), 121.70 (q, J = 318.2 Hz), 120.81 (d, J' = 22.2 Hz), 116.45 (d, J' = 28.0 Hz), 21.47; ESI-MS: m/z calcd for $C_{18}H_{15}F_2N_2O_2S$ [M-TFO⁻]⁺: 361.1; found: 361.0; ESI-HRMS: m/z calcd for $C_{18}H_{15}F_2N_2O_2S$ [M-TFO⁻]⁺: 361.0817; found: 361.0807.

3-chloro-1-(2-(4-methylphenylsulfonamido)phenyl)pyridin-1-i-um trifluoromethanesulfonate (4af)⁸. yellow solid (193 mg, 0.38 mmol, 76%). ¹H NMR (301 MHz, METHANOL-D3): δ 9.41 (s, 1H), 9.07 (d, J = 6.0 Hz, 1H), 8.86 (d, J = 8.3 Hz, 1H), 8.27 (d, J = 7.1 Hz, 1H), 7.9 - 7.7 (m, 1H), 7.53 (d, J = 7.4 Hz, 4H), 7.36 (d, J = 6.9 Hz, 2H), 7.05 (d, J = 25.2 Hz, 1H), 2.40 (s, 3H); ¹³C NMR (76 MHz, METHANOL-D3): δ 147.97, 147.53, 146.81, 145.98, 140.73, 136.46, 136.34, 133.82, 132.08, 130.84 (2 \times CH), 130.26, 129.81, 129.38, 128.44 (2 \times CH), 126.90, 121.72 (q, J = 318.5 Hz), 21.49; ESI-MS: m/z calcd for $C_{18}H_{16}ClN_2O_2S$ [M-TFO⁻]⁺: 359.1; found: 359.1; ESI-HRMS: m/z calcd for $C_{18}H_{16}ClN_2O_2S$ [M-TFO⁻]⁺: 359.0616; found: 359.0613.

3-chloro-1-(3-fluoro-2-(4-methylphenylsulfonamido)-phenyl)pyridin-1-i-um trifluoromethanesulfonate (4ff). yellow solid (110 mg, 0.21 mmol, 42%). ¹H NMR (400 MHz, METHANOL-D3) δ 9.58 (s, 1H), 9.18 (d, J = 6.0 Hz, 1H), 8.92 - 8.86 (m, 1H), 8.28 (dd, J = 8.5, 6.1 Hz, 1H), 7.66 (ddd, J = 13.2, 9.6, 6.3 Hz, 2H), 7.51 (d, J = 8.3 Hz, 2H), 7.47 - 7.40 (m, 1H), 7.30 (d, J = 8.2 Hz, 2H), 2.42 (s, 3H); ¹³C NMR (151 MHz, METHANOL-D3) δ 158.63 (d, J' = 254.9 Hz), 147.04, 146.36, 145.60, 144.62, 136.03, 135.21, 130.10 (d, J' = 9.2 Hz), 129.54, 129.40 (2 \times CH, 1 \times C), 128.07, 126.97 (2 \times CH), 122.84 (d, J' = 2.3 Hz), 120.43 (q, J = 318.2 Hz), 119.62 (d, J' = 21.0 Hz), 20.19; ESI-MS: m/z calcd for $C_{18}H_{15}ClFN_2O_2S$ [M-TFO⁻]⁺: 377.1; found: 377.0; ESI-HRMS: m/z calcd for $C_{18}H_{15}ClFN_2O_2S$ [M-TFO⁻]⁺: 377.0521; found: 377.0523.

3-chloro-1-(5-fluoro-2-(4-methylphenylsulfonamido)-phenyl)pyridin-1-i-um trifluoromethanesulfonate (4hf). yellow solid (197 mg, 0.38 mmol, 75%). ¹H NMR (301 MHz, METHANOL-D3): δ 9.53 (s, 1H), 9.15 (d, J = 5.3 Hz, 1H), 8.92 (d, J = 8.4 Hz, 1H), 8.31 (dd, J = 7.9, 5.7 Hz, 1H), 7.80 (d, J = 7.7 Hz, 1H), 7.52 (d, J = 8.0 Hz, 2H), 7.40 (t, J = 12.1 Hz, 3H), 6.93 (dd, J = 8.0, 4.9 Hz, 1H), 2.47 (s, 3H); ¹³C NMR (76 MHz, METHANOL-D3) δ 161.35 (d, J' = 251.6 Hz), 147.18, 146.35, 145.57, 144.89, 140.35 (d, J' = 13.7 Hz), 135.26, 135.14, 134.85, 131.17 (d, J' = 8.8 Hz), 129.67 (2 \times CH),

128.16, 127.25 (2 \times CH), 120.44 (q, J = 318.6 Hz), 119.48 (d, J^2 = 22.4 Hz), 115.16 (d, J^2 = 27.7 Hz), 20.25; ESI-MS: m/z calcd for $C_{18}H_{15}ClFN_2O_2S$ [M-TFO⁻]⁺: 377.1; found: 377.0; ESI-HRMS: m/z calcd for $C_{18}H_{15}ClFN_2O_2S$ [M-TFO⁻]⁺: 377.0521; found: 377.0514.

3-fluoro-1-(5-fluoro-2-(4-methylphenylsulfonamido)-phenyl)pyridin-1-i-um trifluoromethanesulfonate (4kf). yellow solid (147 mg, 0.38 mmol, 75%). ¹H NMR (301 MHz, METHANOL-D3): δ 9.23 (s, 1H), 8.91 (d, J = 5.8 Hz, 1H), 8.77 (d, J = 8.4 Hz, 1H), 8.16 (dd, J = 8.2, 6.2 Hz, 1H), 7.69 (d, J = 1.9 Hz, 1H), 7.51 (d, J = 8.0 Hz, 2H), 7.41 (dd, J = 8.6, 1.9 Hz, 1H), 7.26 (d, J = 7.9 Hz, 2H), 7.12 (d, J = 8.6 Hz, 1H), 2.35 (s, 3H); ¹³C NMR (76 MHz, METHANOL-D3): δ 147.63, 147.37, 146.71, 144.24, 139.89, 138.69, 137.44, 136.34, 133.30, 130.62 (2 \times CH), 129.55, 129.28, 128.21, 127.79 (2 \times CH), 127.51, 121.75 (q, J = 319.2 Hz), 21.43; ESI-MS: m/z calcd for $C_{18}H_{15}Cl_2N_2O_2S$ [M-TFO⁻]⁺: 393.0; found: 393.1; ESI-HRMS: m/z calcd for $C_{18}H_{15}Cl_2N_2O_2S$ [M-TFO⁻]⁺: 393.0226; found: 393.0224.

1-(5-bromo-2-(4-methylphenylsulfonamido)phenyl)-3-chloropyridin-1-i-um trifluoromethanesulfonate (4nf). yellow solid (199 mg, 0.34 mmol, 68%). ¹H NMR (400 MHz, DMSO-D6) δ 9.49 (s, 1H), 9.06 (d, J = 5.1 Hz, 1H), 8.91 (d, J = 8.2 Hz, 1H), 8.27 (t, J = 6.3 Hz, 1H), 7.89 (s, 1H), 7.52 (t, J = 8.7 Hz, 3H), 7.26 (d, J = 7.1 Hz, 2H), 7.12 (d, J = 8.7 Hz, 1H), 2.33 (s, 3H); ¹³C NMR (101 MHz, DMSO-D6) δ 146.67, 146.32, 146.02, 145.98, 142.29, 139.90, 136.33, 134.97, 134.29, 134.16, 129.84 (2 \times CH), 129.48, 128.54, 126.77 (2 \times CH), 125.57, 120.99 (q, J = 321.7 Hz), 21.39; ESI-MS: m/z calcd for $C_{18}H_{15}BrClN_2O_2S$ [M-TFO⁻]⁺: 437.0; found: 437.2; ESI-HRMS: m/z calcd for $C_{18}H_{15}BrClN_2O_2S$ [M-TFO⁻]⁺: 436.9721; found: 436.9722.

3-chloro-1-(2-(4-methylphenylsulfonamido)-5-(trifluoromethoxy)phenyl)pyridin-1-i-um trifluoromethanesulfonate (4af). yellow solid (193 mg, 0.33 mmol, 65%). ¹H NMR (400 MHz, METHANOL-D3) δ 9.46 (s, 1H), 9.08 (d, J = 5.3 Hz, 1H), 8.86 (d, J = 8.2 Hz, 1H), 8.24 (t, J = 6.2 Hz, 1H), 7.88 (s, 1H), 7.58 - 7.46 (s, 3H), 7.34 (d, J = 6.8 Hz, 2H), 7.06 (d, J = 7.0 Hz, 1H), 2.43 (s, 3H); ¹³C NMR (101 MHz, DMSO-D6) δ 147.37, 146.96, 146.26, 145.09, 144.06, 137.45, 136.85, 134.43, 130.23 (2 \times CH), 128.84, 127.87, 127.27 (2 \times CH), 126.31 (q, J = 63.0 Hz), 125.39, 122.76, 121.15 (q, J = 322.2 Hz), 120.40 (q, J = 258.0 Hz), 21.51; ESI-MS: m/z calcd for $C_{19}H_{15}ClF_3N_2O_3S$ [M-TFO⁻]⁺: 443.0; found: 443.1; ESI-HRMS: m/z calcd for $C_{19}H_{15}ClF_3N_2O_3S$ [M-TFO⁻]⁺: 443.0439; found: 443.0436.

Synthesis of methyl 4-(4-methylphenylsulfonamido)benzoate (7). Cu(OTf)₂ (18.1 mg, 0.05 mmol) was added to a mixture of mesityl(4-methoxycarbonyl)phenyl)iodonium trifluoromethanesulfonate **1q** (265.2mg, 0.5mmol) and (3-chloropyridin-1-i-um-1-yl)(tosyl)amide **2f** (141.4mg, 0.5mmol) in a sealed tube. Then the tube was evacuated and recharged with N₂ for 3 times. After 2 mL of dichloroethane was added, the tube was sealed and the mixture was allowed to stir at 130 °C for 48 h until completion of the reaction checked by TLC. At last the desired compound **7** was purified by silica gel column chromatography petroleum ether/ethyl acetate = 10:1) as a yellow solid (93 mg, 0.3 mmol, 61%). ¹H NMR (400 MHz, CHLOROFORM-D) δ 7.84 (d, J = 8.7 Hz, 2H), 7.66 (d, J = 8.3 Hz, 2H), 7.26 (s, 1H), 7.17 (d, J = 8.2 Hz, 2H), 7.07 (d, J = 8.7 Hz, 2H), 3.80 (s, 3H), 2.31 (s, 3H); ¹³C NMR (101 MHz, CHLOROFORM-D) δ 166.50, 144.52, 141.07, 135.79, 131.18 (2 \times CH), 129.96 (2 \times CH), 127.35 (2 \times CH), 126.22, 119.06 (2 \times CH), 52.22, 21.67; ESI-MS: m/z calcd for $C_{15}H_{16}NO_4S$ [M+H]⁺: 306.1; found: 306.6; ESI-HRMS: m/z calcd for $C_{15}H_{16}NO_4S$ [M+H]⁺: 306.0800; found: 306.0801.

3-chloro-1-(4-methyl-2-(4-methylphenylsulfonamido)-phenyl)pyridin-1-i-um trifluoromethanesulfonate (4cf-1), 3-chloro-1-(2-methyl-6-(4-methylphenylsulfonamido)-phenyl)pyridin-1-i-um trifluoromethanesulfonate (4cf-2), 3-chloro-1-(4-methyl-2-(4-methylphenylsulfonamido)-5-(trifluoromethoxy)phenyl)pyridin-1-i-um trifluoromethanesulfonate (4cf-3).

(fonamido)phenyl)pyridin-1-i um trifluoromethanesulfonate (4cf-2). yellow solid (178 mg, 0.34 mmol, 68% (3: 2)). ¹H NMR (400 MHz, METHANOL-D3) δ 9.38 (s, 2H), 9.02 (d, *J* = 6.0 Hz, 1H), 8.97 (d, *J* = 6.1 Hz, 1H), 8.89 (dd, *J* = 8.7, 0.9 Hz, 1H), 8.81 (dd, *J* = 8.7, 0.8 Hz, 1H), 8.27 (dd, *J* = 8.5, 6.1 Hz, 1H), 8.22 (dd, *J* = 8.5, 6.2 Hz, 1H), 7.63 (d, *J* = 8.2 Hz, 1H), 7.53 (d, *J* = 8.3 Hz, 1H), 7.46 (t, *J* = 6.9 Hz, 2H), 7.44 - 7.37 (m, 2H), 7.37 - 7.31 (m, 4H), 6.75 (dd, *J* = 7.5, 1.3 Hz, 1H), 6.69 (s, 1H), 2.42 (s, 5H), 2.26 (s, 3H), 2.18 (s, 2H); ¹³C NMR (101 MHz, METHANOL-D3) δ 147.19, 146.91, 146.40, 146.23 (1×CH, 1×C), 145.59, 144.52, 144.48, 143.73, 139.00, 136.94, 135.75, 135.50, 135.44, 135.10, 134.83, 132.10, 131.89, 130.92, 130.42, 129.58 (2×CH), 129.50 (2×CH), 129.07, 129.00, 128.39, 128.05, 127.21 (2×CH), 127.15 (2×CH), 126.66, 126.28, 125.20, 122.03, 118.86, 115.69, 20.24, 20.23, 19.77, 16.28; ESI-MS: m/z calcd for C₁₉H₁₈ClN₂O₂S [M-TFO]⁺: 373.1; found: 373.1; ESI-HRMS: m/z calcd for C₁₉H₁₈ClN₂O₂S [M-TFO]⁺: 373.0772; found: 373.0774.

1-(5-methyl-2-(phenylsulfonamido)phenyl)pyridin-1-i um trifluoromethanesulfonate (4dg)⁸. yellow solid (178 mg, 0.38 mmol, 75%). ¹H NMR (400 MHz, METHANOL-D3) δ 9.06 (d, *J* = 5.5 Hz, 2H), 8.77 (t, *J* = 7.9 Hz, 1H), 8.24 (t, *J* = 6.8 Hz, 1H), 7.65 (t, *J* = 7.3 Hz, 1H), 7.63 - 7.56 (m, 3H), 7.52 (t, *J* = 7.7 Hz, 2H), 7.32 (d, *J* = 8.2 Hz, 1H), 6.70 (d, *J* = 8.2 Hz, 1H), 2.43 (s, 3H); ¹³C NMR (101 MHz, METHANOL-D3) δ: 146.92, 146.70 (2×CH), 140.60, 140.15, 138.14, 133.34, 132.72, 129.06 (2×CH), 128.90, 127.63, 127.57, 127.51 (2×CH), 127.17 (2×CH), 120.45 (q, *J* = 318.5 Hz), 19.56; ESI-MS: m/z calcd for C₁₈H₁₇N₂O₂S [M-TFO]⁺: 325.1; found: 325.2; ESI-HRMS: m/z calcd for C₁₈H₁₇N₂O₂S [M-TFO]⁺: 325.1005; found: 325.1004.

(Z)-1-((phenoxy(phenyl)methylene)amino)pyridin-1-i um hexafluorophosphate(V) (6a). Cu(OTf)₂ (18.1 mg, 0.05 mmol) was added to a mixture of diphenyliodonium hexafluorophosphate(V) **1a** (213 mg, 0.5mmol) and benzoyl(pyridin-1-i um-1-yl)amide **5a** (99.1 mg, 0.5mmol) in a sealed tube. Then the tube was evacuated and recharged with N₂ for 3 times. After 2 mL of dichloroethane was added, the tube was sealed and the mixture was allowed to stir at 130 °C for 48 h until completion of the reaction checked by TLC. At last the desired compound **6a** was purified by silica gel column chromatography (dichloromethane/petroleum ether/methanol = 5:3:1) as a yellow solid (137 mg, 0.33 mmol, 65%). ¹H NMR (301 MHz, DMSO-D6): δ 9.24 (d, *J* = 5.9 Hz, 2H), 8.52 (t, *J* = 8.3 Hz, 1H), 8.19 (t, *J* = 7.1 Hz, 2H), 7.77 - 7.69 (m, 2H), 7.54 (t, *J* = 7.4 Hz, 1H), 7.43 (t, *J* = 7.5 Hz, 2H), 7.26 - 7.17 (m, 2H), 7.09 (dd, *J* = 17.5, 7.4 Hz, 3H); ¹³C NMR (76 MHz, DMSO-D6) δ 166.95, 153.26, 144.50, 141.60, 141.31, 133.32, 130.11 (4×CH), 128.88 (2×CH), 128.67 (2×CH), 126.76, 126.16, 119.86 (2×CH); ESI-MS: m/z calcd for C₁₈H₁₅N₂O [M-PF₆]⁺: 275.1; found: 275.2.; ESI-HRMS: m/z calcd for C₁₈H₁₅N₂O [M-PF₆]⁺: 275.1179; found: 275.1178.

X-ray crystal structure analysis of compound 6a. Single crystals suitable for X-ray analysis were obtained by slow evaporation of its solution in CH₃OH. The crystal structure has been deposited at the Cambridge Crystallographic Data Centre and allocated the deposition number: CCDC 1008473. Formula: C₁₈H₁₅F₆N₂OP, *M* = 420.29, colourless crystal, 0.28 x 0.25 x 0.19 mm, *a* = 13.927(3), *b* = 10.771(2), *c* = 24.361(5) Å, α = 90, β = 93.49(3), γ = 90, *V* = 3647.6(13) Å³, ρ_{calc} = 1.531 gcm⁻³, μ = 0.221 mm⁻¹, *Z* = 8, Monoclinic, space group C2/c, λ = 0.71073 Å, *T* = 173(2) K. Data completeness = 0.997, Theta (max) = 27.47, R (reflections) = 0.0567, wR2 (reflections) = 0.1107 (4173).

Synthesis of (Z)-3-methyl-1-((phenoxy(phenyl)methylene)amino)pyridin-1-i um hexafluorophosphate(V) (6b). Cu(OTf)₂ (18.1 mg, 0.05 mmol) was added to a mixture of diphenyliodonium hexafluorophosphate(V) **1a** (213 mg, 0.5mmol) and (2-methylpyridin-1-i um-1-yl)(tosyl)amide **5b** (131.2 mg, 0.5mmol) in a

sealed tube. Then the tube was evacuated and recharged with N₂ for 3 times. After 2 mL of dichloroethane was added, the tube was sealed and the mixture was allowed to stir at 130 °C for 48 h until completion of the reaction checked by TLC. At last the desired compound **6b** was purified by silica gel column chromatography (dichloromethane/petroleum ether/methanol = 5:3:1) as a yellow solid (145 mg, 0.34 mmol, 67%). ¹H NMR (301 MHz, DMSO-D6) δ 9.23 (s, 1H), 9.17 (d, *J* = 6.1 Hz, 1H), 8.44 (d, *J* = 8.0 Hz, 1H), 8.17 (t, *J* = 7.1 Hz, 1H), 7.85 - 7.75 (m, 2H), 7.62 (dd, *J* = 10.5, 4.3 Hz, 1H), 7.52 (dd, *J* = 8.2, 7.0 Hz, 2H), 7.30 (dd, *J* = 11.2, 4.5 Hz, 2H), 7.24 - 7.10 (m, 3H), 2.53 (s, 3H); ¹³C NMR (76 MHz, DMSO-D6): δ 167.34, 153.75, 145.31, 141.19, 140.23, 139.12, 133.84, 130.62 (2×CH), 130.52 (2×CH), 129.44 (2×CH), 128.33, 127.35, 126.66, 120.40 (2×CH), 18.47; ESI-MS: m/z calcd for C₁₉H₁₇N₂O [M-PF₆]⁺: 289.1; found: 289.1; ESI-HRMS: m/z calcd for C₁₉H₁₇N₂O [M-PF₆]⁺: 289.1334; found: 289.1333.

Acknowledgements

This work was supported by National Natural Science Foundation of China (21102080, 21372138) and Tsinghua University Initiative Scientific Research Program (2011Z02150).

Notes and references

- (a) L. A. Thompson and J. A. Ellman, *Chem. Rev.*, 1996, **96**, 555; (b) R. Ballini, A. Palmier and L. Barboni, *Chem. Commun.*, 2008, 2975.
- (a) W. Reppe and W. J. Schreckendiek, *Justus Liebigs Ann. Chem.*, 1948, **560**, 104; (b) R. R. Jones and R. G. Bergman, *J. Am. Chem. Soc.*, 1972, **94**, 660; (c) R. G. Bergman, *Acc. Chem. Res.*, 1973, **6**, 25; (d) K. P. C. Vollhardt, *Acc. Chem. Res.*, 1977, **10**, 1; (e) K. P. C. Vollhardt, *Angew. Chem. Int. Ed. Engl.*, 1984, **23**, 539; (f) T. Takahashi, Z. Xi, A. Yamazaki, Y. Liu, K. Nakajima and M. Kotora, *J. Am. Chem. Soc.*, 1998, **120**, 1672; (g) D. Suzuki, H. Urabe and F. Sato, *J. Am. Chem. Soc.*, 2001, **123**, 7925; (h) Y. Yamamoto, J. Ishii, H. Nishiyama and K. Itoh, *J. Am. Chem. Soc.*, 2004, **126**, 3712; (i) T. Arakawa, R. Ogawa and K. Itoh, *J. Am. Chem. Soc.*, 2003, **125**, 12143; (j) C. Xi, C. Chen, J. Lin and X. Hong, *Org. Lett.* 2005, **7**, 347.
- (a) G. Olah, *Friedel-Crafts and Related Reactions*, Vols. 1-4, Wiley Inter science, New York, 1963; (b) D. E. Pearson and C. A. Buehler, *Synthesis*, 1972, 533.
- V. Sniekus, *Chem. Rev.*, 1990, **90**, 879.
- (a) V. Ritleng, C. Sirlin and M. Pfeffer, *Chem. Rev.*, 2002, **102**, 1731; (b) D. Alberico, M. E. Scott and M. Lautens, *Chem. Rev.*, 2007, **107**, 174; (c) R. Giri, B.-F. Shi, K. M. Engle, N. Maugel and J. -Q. Yu, *Chem. Soc. Rev.*, 2009, **38**, 3242; (d) D. A. Colby, R. G. Bergman and J. A. Ellman, *Chem. Rev.*, 2010, **110**, 624; (e) I. A. I. Mkhald, J. H. Barnard, T. B. Marder, J. M. Murphy and J. F. Hartwig, *Chem. Rev.*, 2010, **110**, 890; (f)

- T. W. Lyons and M. S. Sanford, *Chem. Rev.*, 2010, **110**, 1147; (g) C. -L. Sun, B. -J. Li and Z. -J. Shi, *Chem. Rev.*, 2011, **111**, 1293; (h) L. Kermann, *Chem. Rev.*, 2011, **111**, 1315; (i) P. B. Arockiam, C. Bruneau and P. H. Dixneuf, *Chem. Rev.*, 2012, **112**, 5879.
- 6 (a) K. Fries and G. Finck, *Chem. Ber.*, 1908, **41**, 4271; (b) K. Fries, and W. Pfaffendorf, *Chem. Ber.*, 1910, **43**, 212.
- 7 (a) M. Bielawski, M. Zhu and B. Olofsson, *Adv. Synth. Catal.*, 2007, **349**, 2610; (b) M. Bielawski and B. Olofsson, *Chem. Commun.*, 2007, **2521**; (c) B. Olofsson, *Org. Synth.*, 2009, **86**, 308; (d) E. Skucas and D. W. C. MacMillan, *J. Am. Chem. Soc.*, 2012, **134**, 9090.
- 8 J. Peng, C. Chen, Y. Wang, Z. Lou, M. Li, C. Xi and H. Chen, *Angew. Chem. Int. Ed.*, 2013, **52**, 7574.
- 9 J. A. Bull, J. J. Mousseau, G. Pelletier and A. B. Charette, *Chem. Rev.*, 2012, **112**, 2642.
- 10 CCDC number of **3kb** is 1008472.
- 11 CCDC number of **4da** is 1008474.
- 12 CCDC number of **6a** is 1008473.
- 13 The generation and properties of pyridinium radical were investigated by mass spectrometry or ESR: (a) V. E. Bondybey, J. H. English and R. H. Shiley, *J. Chem. Phys.*, 1982, **77**, 15; (b) M. Shiotani, H. Kawazoe and J. Sohma, *J. Phys. Chem.*, 1984, **88**, 2220; (c) S. J. Yu, C. L. Holliman, D. L. Rempel and M. L. Gross, *J. Am. Chem. Soc.*, 1993, **115**, 9676; (d) M. A. Trikoupis, D. J. Lavoratob, J. K. Terlouw, P. J. A. Ruttink and P. C. Burgers, *Eur. Mass Spectrom.*, 1999, **5**, 431; (e) J. A. LaVerne, I. Carmichael and M. S. Araos, *J. Phys. Chem. A*, 2005, **109**, 461; (f) K. J. Jobst, J. De Winter, R. Flammang, J. K. Terlouw and P. Gerbauxb, *Int. J. Mass Spectrom.*, 2009, **286**, 83.
- 14 S. F. Nelsen and R. T. Landis, *J. Am. Chem. Soc.*, 1973, **95**, 8707.
- 15 Selected examples of vicinal difunctionalization strategy for benzene derivatives: (a) R. A. Abramovitch, S. Kato and G. M. Singer, *J. Am. Chem. Soc.*, 1971, **93**, 3074; (b) R. A. Abramovitch, M. N. Inbasekaran, S. Kato and G. M. Singer, *J. Org. Chem.*, 1976, **41**, 1717; (c) J. A. Blake, D. A. Pratt, S. Lin, J. C. Walton, P. Mulder and K. U. Ingold, *J. Org. Chem.*, 2004, **69**, 3112; (d) A. Porzelle, M. D. Woodrow and N. C. O. Tomkinson, *Org. Lett.* 2010, **12**, 812.
- 16 (a) J. Zhao, C. Wu, P. Li, W. Ai, H. Chen, C. Wang, R. C. Larock and F. Shi, *J. Org. Chem.*, 2011, **76**, 6837; (b) K. Harju, L. Kyylanlahti, T. Paananen, J. Nielsen and J. Yli-Kauhaluoma, *J. Comb. Chem.*, 2006, **8**, 344.